The adventitia has been recognized to play important roles in vascular oxidative stress, remodeling, and contraction. We recently demonstrated that adventitial fibroblasts are able to express endothelin (ET)-1 in response to ANG II. However, it is unclear whether ET-1 receptors are expressed in the adventitia. We therefore investigated the expression and roles of both ETA and ETB receptors in collagen synthesis and ET-1 clearance in adventitial fibroblasts. Adventitial fibroblasts were isolated and cultured from the mouse thoracic aorta by the explant method. Cultured cells were treated with ANG II (100 nmol/l) or ET-1 (10 pM) in the presence or absence of the ANG II type 1 receptor antagonist losartan (100 M), the ET-1 receptor antagonists BQ-123 (ET A receptor, 1 M) and BQ-788 (ET B receptor, 1 M), and the ETB receptor agonist sarafotoxin 6C (100 nM). ET-1 peptide levels were determined by ELISA, whereas ET A, ETB, and collagen levels were determined by Western blot analysis. ANG II increased ET-1 peptide levels in a timedependent manner. ANG II increased ET A and ETB receptor protein levels as well as collagen in a similar fashion. ANG II-induced collagen was reduced while in the presence of BQ-123, suggesting a role for the ET A receptor in the regulation of the extracellular matrix. ANG II treatment in the presence of BQ-788 significantly increased ET-1 peptide levels. Conversely, the ET B receptor agonist sarafotoxin 6C significantly decreased ET-1 peptide levels. These data implicate a role for the ET B receptor in the clearance of the ET-1 peptide. In conclusion, both ET A and ETB receptors are expressed in adventitial fibroblasts, which paves the ground for the biological significance of adventitial ET-1. The ET A receptor subtype mediates collagen I expression, whereas the ET B receptor subtype may play a protective role through increasing the clearance of the ET-1 peptide. adventia; endothelin-1; endothelin type A receptor; endothelin type B receptor THE ROLE OF ANG II in the development of hypertension and atherosclerosis has been well accepted. It has been demonstrated that endothelin (ET)-1 can contribute to many ANG II-mediated responses (8).
Recent evidence has suggested that the adventitia of the blood vessel is a dynamic tissue (13) . The adventitia has been identified as a major producer of ROS (38) , reacting to vasoactive hormones such as ANG II (29) . Moreover, local production of ET-1 within the adventitia has been recently reported after ANG II treatment (1) . Although it has been reported that the ET A receptor is expressed in vessels originating from adventitial cells by a bioengineering method (19) , the specific function of ET receptors within the adventitia is unknown. Knowledge of the existence of ET A and ET B receptors in adventitial fibroblasts would provide the framework for the biological effects of this adventitial ET-1 in the regulation of vascular function.
In this study, the expression and function of the ET receptors in the adventitia were investigated. Pharmacological agents to block ET-mediated effects have been developed to treat vascular disease associated with elevated ET-1 levels. By understanding the role of the local adventitial ET-1 system, a greater knowledge of the vessel ET-1 system may be established and, therefore, may aid in the decision of specific ET antagonists to treat vascular disease.
METHODS
The animals, tissue preparation, and primary culture of adventitial fibroblasts have been previously reported.
Cell treatment. Cells were grown to subconfluence and incubated in serum-free medium for 24 h. Cells were treated with ANG II at 100 nmol/l for 0.5, 1, 1.5, 3, 6, or 24 h. Responses to ANG II were determined in the absence or presence of the ANG II type 1 (AT 1) receptor antagonist losartan (100 M). Cells and media were then collected. Aliquots were taken for the determination of the protein concentration with the use of Bio-Rad Bradford Protein Assay Dye Reagent. The remaining solution and harvested cells were stored in a Ϫ80°C freezer for ET-1 peptide, ET A receptor, ETB receptor, and collagen type I protein determination. ET-1 peptide measurements were determined from the cell culture medium via ELISA, whereas Western blot analysis was used for ET A receptor, ETB receptor, and collagen type I protein from whole cell lysates.
The role of ET-1 receptors in collagen synthesis and ET-1 clearance was tested by comparing the ANG II-induced collagen type I production and ET-1 release with or without BQ-123 (1 M), an ET A receptor antagonist, and BQ-788 (1 M), an ETB receptor antagonist.
Measurement of ET-1 peptide levels by ELISA. After treatments, cell culture media were collected for ET-1 level measurements with a commercial ELISA kit from R&D Systems (Minneapolis, MN) according to the manufacturer's instructions. ET-1 release was expressed as picograms of ET-1 per milliliter.
Measurement of protein expression by Western blot analysis. Cells were cultured with or without different treatments for various times and lysed with lysis buffer. The measurement of protein by means of Western blot analysis followed the same protocol as that used by An et al. (1) . Equal amounts of protein samples (10 g) were separated by electrophoresis with 7% SDS-PAGE under reducing conditions and transferred to a 0.2-m polyvinylidene difluoride membrane. Membranes were then incubated in blocking buffer containing 5% nonfat dry milk powder (Carnation) for 1 h. ETA receptors, ETB receptors, and collagen type I were detected by incubating the membrane with the appropriate dilutions (Table 1 ) overnight at 4°C. Membranes were then incubated with a 1:2,000-diluted secondary peroxidase-conjugated antibody (Table 1 ) and detected by the ECL detection system (Amersham Pharmacia Biotech) according to the manufacturer's instructions.
Chemicals. ANG II, BSA, poly-L-lysine solution, antibiotic-antimycotic solution, PMSF, PBS, Tris-acetate sample buffer, Tween 20, trypsin-EDTA, and rabbit ␤-actin monoclonal antibody were from Sigma. ET-1, BQ-123, BQ-788, and sarafotoxin 6C (S6C) were from American Peptide. Isoflurane was from Baxter, and the DMEM and F-12 nutrient mixture (DMEM-F-12) was from VWR. FBS was from Hyclone. Cell lysis buffer and anti-rabbit horseradish peroxidase conjugate were from Cell Signaling. Nonfat dry milk powder was from Carnation, collagen type I goat polyclonal antibody and donkey anti-goat horseradish peroxidase conjugates were from Santa Cruz Biotechnology, and rabbit ET A polyclonal antibody and rabbit ETB polyclonal antibody were from Chemicon. Rabbit ␣-actin polyclonal was from Abcam. Donkey anti-rabbit Alexa fluor 488 and 546 secondary antibodies were from Invitrogen. The ELISA kit was purchased from R&D Systems.
Data analysis. Analysis of the data was performed using the SPSS statistical software program. One-way and two-way (used when doing two-way comparisons) ANOVA with a Tukey's post hoc test were used to determine statistical significance. Data are expressed as means Ϯ SE, and significance was accepted when P Յ 0.05.
RESULTS

ANG II-induced ET-1 expression is time dependent.
ANG II (100 nM) induction of the ET-1 peptide at various time periods after treatment as determined by ELISA is shown in Fig. 1 . The basal ET-1 level from cultured fibroblasts before ANG II stimulation was 0.20 Ϯ 0.35 pg/ml (n ϭ 5). Although ANG II increased ET-1 release after 2-6 h of ANG II incubation, these increases were not statistically significant (P Ͼ 0.05). Maximal ANG II-induced ET-1 peptide was seen at 24 h of ANG II incubation and was 2.10 Ϯ 0.45 pg/ml (P Ͻ 0.05). Pretreatment with losartan blocked the elevations in ET-1 expression evoked by ANG II, suggesting that the induction was mediated by AT 1 receptors.
ANG II induces ET A expression. As a first step, we examined the specificity of the ET A antibody. As a negative control, the cell lysate was incubated for 1 h with an antibody that was preoccupied by its antigen, and the positive control was a control antigen provided by the manufacturer (Chemicon). The negative control provided no band, whereas the positive control provided a single band at ϳ50 kDa ( Fig. 2A) . These data demonstrated the high specificity of the ET A receptor antibody.
The effect of ANG II on ET A receptor expression at various time periods after treatment is shown in Fig. 2B . ANG II induced an increase of ET A receptor levels that followed a time-dependent manner. There was no significant amount of ET A receptor expressed in control cells. No difference in ET A receptor density was seen at 1 and 2 h of ANG II treatment (P Ͼ 0.05). However, significant increases in receptor density were seen at 4, 6, and 24 h of ANG II treatment (n ϭ 4, P Ͻ 0.05).
ANG II induces ET B expression. Similar to that described above for ET A receptors, the negative control provided no band, whereas the positive control provided a single band at ϳ35 kDa (Fig. 3A) , demonstrating the high specificity of the ET B receptor antibody.
The time course of ANG II-induced ET B receptor expression is shown in Fig. 3B . Similar to the expression of ET A receptors, ANG II induced an increase of ET B receptor levels following a time-dependent manner. There was no significant amount of ET B receptor expressed in control cultured fibroblasts. No increase in ET B receptor expression was observed at 1 and 2 h of ANG II treatment (P Ͼ 0.05). However, significant increases in receptor density were seen at 4, 6, and 24 h of ANG II treatment (P Ͻ 0.01).
Role of ET A in ANG II-induced collagen type I expression. ANG II (100 nM)-induced collagen type I expression at different time periods after treatment is shown in Fig. 4 . A negative control for the collagen antibody was not used as collagen detection in the adventitia by the collagen I antibody has previously been reported (2) . In control cells, collagen I levels were detectable at ϳ126 kDa. ANG II induced a time- dependent increase in collagen I expression, where significant increases were observed between 4 and 24 h of treatment compared with control (P Ͻ 0.05). These data parallel the expression levels of ET A receptors.
The effect of ET-1 receptor antagonists on the expression of collagen type I protein is shown in Fig. 5 . As expected, incubation with 100 nM ANG II for 6 h induced a significant increase in collagen type I (P Ͻ 0.05). Importantly, the increase in collagen type I expression induced by ANG II was inhibited by the ET A receptor antagonist BQ-123 (P Ͻ 0.05 compared with ANG II alone) but not by the ET B receptor antagonist BQ-788 (P Ͼ 0.05 compared with ANG II alone).
Role of ET B receptors in ET-1 clearance.
To test the hypothesis that ET B receptors increase ET-1 clearance, we used two approaches: 1) ANG II-induced ET-1 compared in the absence and presence of an ET B antagonist and 2) treatment of cells with a known concentration of ET-1. ET-1 levels in the medium were compared with peptide levels in the presence of an ET B receptor agonist. The effect of the ET B receptor antagonist BQ-788 (100 nM) on ANG II-induced ET-1 peptide levels is shown in Fig. 6 . Incubation with ANG II in the presence of BQ-788 (ANG II ϩ BQ-788) dramatically increased ANG II-induced ET-1 levels, and significant ET-1 levels were seen at 4, 6, and 24 h of treatment (P Ͻ 0.05).
To further explore the role of the ET B receptor in the clearance of ET-1, ET-1 was added and determined in the presence and absence of the specific ET B receptor agonist S6C. The effect of the ET B receptor-specific agonist S6C (10 nM) on exogenously added ET-1 (10 pM) is shown in Fig. 7 .
The addition of ET-1 for 10 min increased ET-1 levels compared with control levels (P Ͻ 0.05). However, after ET-1 was exogenously added, ET-1 levels did not increase in the presence of the ET B agonist S6C (P Ͼ 0.05).
ANG II infusion induced ET-1 expression and ET receptor changes in vivo. ET-1 protein was expressed throughout the mouse aortic wall (Fig. 8A) . After ANG II infusion, mouse aortas displayed a substantial increase in ET-1 immunoreactivity, which was localized primarily to the adventitia (Fig.  8A) . Furthermore, ET A receptors were also expressed throughout the aortic adventitia and media, although they were somewhat more localized to the medial layer (Fig. 8B) . ET A receptors did not increase in expression after ANG II infusion (Fig.  8B) . Additionally, ET B receptors were expressed throughout the aortic wall but were more localized to the adventitial and endothelial layers (Fig. 8C ). ANG II infusion had no significant effect on ET B receptor expression or localization (Fig. 8C) .
DISCUSSION
In this study, we have provided several lines of evidence and novel findings that illustrate the importance of the adventitiaderived ET system. These findings, which are discussed below, include the expression and importance of adventitia-derived ET-1, expression of the ET A receptor and its role in collagen type I expression, and expression of the ET B receptor and its role in the clearance of the ET-1 peptide.
Increasing evidence supports the role for the adventitia with regard to cardiovascular disease. Adventitial fibroblasts have been shown to be involved in arterial repair (22, 35 ) and serve as a major source of vascular oxidative stress (3, 30, 38, 39) . Inhibition of adventitial oxidative stress has been demonstrated to decrease neointimal proliferation (9), hyperplasia (40) , and smooth muscle hypertrophy (23) .
We (1) have previously demonstrated that aortic adventitial fibroblasts synthesize and release ET-1 peptide after treatment with ANG II, an important hormone involved in blood pressure regulation and the pathogenesis of atherosclerosis. O 2 ·Ϫ is involved in mediating ANG II-induced ET-1. ANG II-stimulated type I ␣ 1 -procollagen mRNA expression and protein synthesis were inhibited by the ET A receptor antagonist, suggesting a potentially biological meaningful role for this interaction at the functional level (1). Additionally, we have demonstrated the existence of ET A and ET B receptors in vascular adventitial fibroblasts (more detailed discussion below).
ANG II-induced ET A expression. In this study, we demonstrate, for the first time, that the ET A receptor protein is expressed in adventitial fibroblasts and modulated by ANG II based on the following evidence. First, expression of the ET A receptor was detected by Western blot analysis of cultured adventitial fibroblasts using a specific antibody against the ET A receptor. The ET A antibody recognized a single band of ϳ50 kDa. The specificity of the antibody was demonstrated by the fact that the band at 50 kDa was abolished if the antibody was preincubated with the antigen provided by the manufacturer, which fully occupies the ET-1-binding sites. Second, ANG II increased ET A receptor density in a time-dependent manner, reaching significance at 6 h of treatment. Third, we found that ANG II-stimulated collagen type I protein synthesis was inhibited by the ET A receptor antagonist BQ-123. Finally, we have demonstrated ET A receptor expression in the adventitial layer of aortas isolated from ANG II-infused mice.
The ET A receptor predominates in VSMCs, although both ET A and ET B receptors have been shown to be located in myocytes and cardiac fibroblasts (33) . Laflamme et al. (19) demonstrated the presence of ET A receptors in the adventitia mediating ET-1-induced vasoconstriction in an adventitia-derived tissue-engineered human blood vessel. Although it parallels well with native vessels in many aspects, such as their structure, receptor expression, and physiological responsiveness, this engineered vessel cannot reproduce the complex structure with multiple adventitial cell types and vasa vasorum (31) . Our data are consistent with the above finding. Importantly, the data were obtained from primary cultured adventitial fibroblasts from the mouse aorta. Primary cultured cells of adventitial fibroblasts are derived from aortic explants and may, therefore, provide a broader interpretation of the results compared with a bioengineered vessel as the primary cultured aortic fibroblast are derived from a functional in vivo tissue, whereas the validity of a bioengineered vessel under in vivo conditions has not yet been determined.
ET A receptor expression has been reported to be differentially regulated by various cell types and stimuli (16, 33) . In this study, we found that ANG II increased ET A receptor expression in a time-dependent manner, reaching significance at 6 h of treatment. However, it has been reported that ANG II treatment did not increase ET A receptor mRNA expression in rat neonatal cardiomyocytes (16) . On the other hand, an upregulation of ET A receptor mRNA and protein expression has been reported in rat hearts with chronic heart failure (17), coinciding with our study.
It has been shown that ET receptor expression induced by ANG II is mediated by the AT 1 receptor subtype (42) . Increased expression of the ET A receptor was also seen after balloon injury of the rat carotid artery (37) . Although the mechanism of the increased ET A receptors found in VSMCs was not investigated, it has been reported that insulin caused an upregulation of the AT 1 receptor that was dependent on an increase in cAMP (26) and p42/44 MAPK activation (25) in rat VSMCs. ANG II has been shown to increase cAMP in VSMCs (15) and p42/44 MAPK (20) ; therefore, upregulation of the ET A receptor as a result of ANG II incubation may be dependent on cAMP and/or p42/44 MAPK.
Role of the ET A receptor in ANG II-induced collagen accumulation. In addition to examining whether ET A receptor expression is upregulated by ANG II, we determined whether the upregulation of this receptor plays any role in collagen expression in cultured fibroblasts. Interestingly, in our study, ET A receptor protein increased in a similar manner to that of collagen type I, where significant levels were seen at 6 and 24 h of ANG II treatment. Incubation with the ET A receptor- specific antagonist BQ-123 significantly inhibited ANG IIinduced collagen type I protein expression. Coinciding with our findings, it has been demonstrated that ET-1-induced collagen expression was dose and time dependent in dermal fibroblasts (34) . ET-1 treatment has been shown to decrease levels of matrix metalloproteinase (MMP)-1, an interstitial collagenase that is responsible for the cleavage of collagen type I and may therefore significantly affect collagen turnover (34) . Activation of the collagen type I reporter and the subsequent suppression of MMP-1 transcription by ET-1 have been shown to be mediated by the ET A receptor (34) .
Similar findings have been reported in other cell types. Fibrotic tissues of failing rat hearts after myocardial infarction had increased expression of ET-1 and the ET A receptor (17).
Blockade of the ET A receptor after myocardial infarction helped reduce collagen synthesis as well as increase the synthesis of MMPs (MMP-13 and MMP-2), enzymes responsible for the breakdown of collagen proteins (11) . The above findings strongly suggest that ANG II-induced collagen type I expression is mediated by ET A receptors.
Expression of the ET B receptor. Another major discovery in this study was that, for the first time, ET B receptor protein was shown to be expressed in adventitial fibroblasts. Using the same methods used to detect ET A receptor protein, expression of the ET B receptor was revealed by Western blot analysis. ANG II increased ET B receptor expression in a time-dependent manner, reaching significance at 6 h of treatment. Furthermore, we demonstrated clear robust expression of the ET B receptor in the adventitia of aortas isolated from ANG II-infused mice. In addition, we (1) have previously found that mRNA levels were low but identifiable in cultured adventitial fibroblasts.
Although the existence of the ET B receptor in ECs and VSMCs is well established, the expression of ET B receptors in the vascular adventitia has been controversial. Immunohistochemical analysis of the capybara basilar artery provided evidence of adventitial ET B receptors (24) . However, results from an earlier study (19) suggested that ET B receptors were not present in the adventitia derived from a tissue-engineered human blood vessel.
The function of the ET B receptor varies in different cell types. Studies (14, 33) investigating the function of the ET B receptor found in vascular ECs determined that the receptor was responsible for mediating vasodilation via the NO-prostacyclin pathway. In contrast, activation of ET B receptors within the medial layer of the blood vessels mediates short-term vasoconstriction (7) .
We demonstrated in the present study that adventitial ET B receptors indeed play a role in the clearance of the ET-1 peptide by two lines of evidences: 1) pharmacological antagonism with a specific ET B antagonist increased ET-1 peptide levels after ANG II treatment and 2) the ET B receptor-specific agonist decreased exogenously added ET-1, supporting the notion that activation of the ET B receptor increases ET-1 clearance.
In this study, ANG II induced a significant increase in ET-1 peptide only after 24 h of treatment, although ANG II-induced ET-1 mRNA significantly increased in adventitial fibroblasts in a shorter time period (1, 2) . Interestingly, examination of the ET B receptor after ANG II treatment provided evidence of maximal receptor expression at 6 h of treatment, where the receptor appeared to downregulate at 24 h of treatment compared with 6 h of treatment. Moreover, antagonism of the ET B receptor by BQ-788 significantly increased ANG II-induced ET-1 peptide levels at all times (4, 6, and 24 h) compared with the values with ANG II alone. This result coincides with a previous study (18) that investigated ET B receptor and ET-1 peptide levels in rats with pulmonary congestion secondary to chronic heart failure. Indeed, that study (18) demonstrated and attributed a decrease in ET B receptor protein levels to the elevated ET-1 peptide levels in rats with chronic heart failure. Furthermore, treatment with BQ-788 resulted in a 180% increase in ET-1 peptide levels in human ECs (27) .
We also demonstrated a role for the ET B receptor in the clearance of the ET-1 peptide through the use of an ET B receptor-specific agonist. The results from our study indicate that activation of the ET B receptor through S6C treatment increased ET-1 clearance as demonstrated by the decrease in exogenously added ET-1 to adventitial fibroblasts. S6C belongs to the sarafotoxin family of peptides and is a highly specific ET B receptor agonist (41) . A recent study (6) provided evidence that the ET B receptor-specific agonist S6C helped reduce infarct size and preserve ET B receptor mRNA in the ischemia-reperfused myocardium of anesthetized rats. The above data support a role for the ET B receptor in clearing ET-1. The possible mechanism by which the ET B receptor mediates ET-1 clearance is discussed in APPENDIX B.
In vitro versus in vivo. ET-1 peptide was increased in the mouse aortic wall in response to ANG II infusion, which is consistent with our findings in cultured cells. Furthermore, both ET A and ET B receptors were expressed in the adventitia, as seen in cultured fibroblasts. However, ANG II infusion did not increase ET A and ET B receptor expression in vivo. This discrepancy from ANG II-induced responses in vivo could result from many factors. It is plausible that expression of ET A and ET B receptors was increased at the earlier stage of ANG II infusion. ANG II could increase ET A and ET B receptor-coupled signaling pathways and, therefore, increase their biological responses even when the receptor expressions remained at the same level.
Conclusions. In summary, adventitial fibroblasts synthesize and release ET-1 in response to stimulation by ANG II. This effect of ANG II is largely mediated by O 2 ·Ϫ . Moreover, we identified specific functions of adventitia-derived ET receptors, which provide the fundamental structure base for ET-1 function. ANG II can increase both ET A and ET B receptors in adventitial fibroblasts. The ET A receptor contributes to the increased levels of collagen type I expression, which has been shown to be associated with fibrosis, increase vessel stiffness, affect vascular compliance, and influence VSMC migration (32) . Furthermore, the upregulation of adventitial ET B receptors may have protective effects through increasing the clearance of ET-1. These data may have important implications in vascular diseases where increased ANG II and ET-1 levels are seen, such as hypertension.
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